Skip to main content
. 2022 Dec 7;28:182–196. doi: 10.1016/j.omto.2022.12.002

Figure 6.

Figure 6

Antitumor effect and in vivo gene silencing of the m-PPDCNPs

(A) Tumor volume of the HCT116 xenograft tumor-bearing nude mice (N = 5) after treatment by PBS, miR-190, Dox, m-PPDCNPs (free miR-190-Cy7) and m-PPDCNPs. ∗ P < 0.05; ∗∗∗ P < 0.005. (B) Weight changes of the HCT116 xenograft tumor-bearing nude mice after treatment by PBS, miR-190, Dox, m-PPDCNPs (free miR-190-Cy7) and m-PPDCNPs. (C, G) CD31 immunohistochemistry staining sections of primary tumors of HCT116 xenograft tumor-bearing nude mice after treatment by PBS, miR-190, Dox, m-PPDCNPs (free miR-190-Cy7) and m-PPDCNPs. ∗∗∗ P < 0.005. Scale bar, 50 μm. (D) Representative photos of mice bearing HCT116 tumors and excised tumors 22 d after treatments. (E) The ICG NIR-II fluorescence imaging evaluate the blood vessels in the tumor area of tumor-carrying mice. (F) Western blot analysis of VEGF expression in the HCT116 tumor tissue after systemic treatment by PBS, miR-190, Dox, m-PPDCNPs (free miR-190-Cy7) and m-PPDCNPs. (H) Immunofluorescent staining of TUNEL or Ki67 expression in tumor tissue sections of HCT116 xenograft tumor-bearing nude mice after treatment by PBS, miR-190, Dox, m-PPDCNPs (free miR-190-Cy7) and m-PPDCNPs. Scale bar: 50 μm.